Publications Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review Citation Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 Sep;16(9):1407-1419.e22. doi: 10.1016/j.cgh.2018.02.051. Epub 2018 Mar 27. PMID: 29596987. Abstract Background & aims: Endpoints in randomized controlled trials (RCTs) of Crohn’s disease (CD) are changing. We performed a systematic review of efficacy and safety outcomes reported in placebo-controlled RCTs of patients with CD. Tags Adverse Effects, Anti-Inflammatory Agents, Crohn's Disease, Diagnosis, Effects, IBD, Inflammatory Bowel Disease, RCT, therapeutic use, Therapy, Treatment, Treatment Outcome Read More
